Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT04090710 |
| Title | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK) |
| Acronym | CYTOSHRINK |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Ontario Clinical Oncology Group (OCOG) |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult | child |
| Covered Countries | CAN | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Peter MacCallum Cancer Centre | Melbourne | 3000 | Australia | Details | ||
| Cross Cancer Institute | Edmonton | Alberta | T6G 1Z2 | Canada | Details | |
| Juravinski Cancer Centre | Hamilton | Ontario | Canada | Details | ||
| Grand River Regional Cancer Centre | Kitchener | Ontario | N2G1G3 | Canada | Details | |
| London Regional Cancer Centre | London | Ontario | N2G1G3 | Canada | Details | |
| The Ottawa Regional Cancer Centre | Ottawa | Ontario | K1H8L6 | Canada | Details | |
| Sunnybrook Health Sciences Centre- Odette Cancer Centre | Toronto | Ontario | M4N3M5 | Canada | Details |